BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang C, Hunt RH. Medical management of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2008;37:879-899, ix. [PMID: 19028323 DOI: 10.1016/j.gtc.2008.09.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Yuan Y, Hunt RH. Evolving issues in the management of reflux disease?: . Current Opinion in Gastroenterology 2009;25:342-51. [DOI: 10.1097/mog.0b013e32832c1504] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
2 Hunt R, Armstrong D, Katelaris P, Afihene M, Bane A, Bhatia S, Chen MH, Choi MG, Melo AC, Fock KM, Ford A, Hongo M, Khan A, Lazebnik L, Lindberg G, Lizarzabal M, Myint T, Moraes-Filho JP, Salis G, Lin JT, Vaidya R, Abdo A, LeMair A; Review Team:. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol. 2017;51:467-478. [PMID: 28591069 DOI: 10.1097/mcg.0000000000000854] [Cited by in Crossref: 56] [Cited by in F6Publishing: 25] [Article Influence: 18.7] [Reference Citation Analysis]
3 Miwa H, Inoue K, Ashida K, Kogawa T, Nagahara A, Yoshida S, Tano N, Yamazaki Y, Wada T, Asaoka D. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33:323-332. [PMID: 21118395 DOI: 10.1111/j.1365-2036.2010.04517.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
4 Lim HC, Kim JH, Youn YH, Lee EH, Lee BK, Park H. Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study. J Neurogastroenterol Motil. 2013;19:495-502. [PMID: 24199010 DOI: 10.5056/jnm.2013.19.4.495] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
5 Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Hunt RH. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci 2020;1482:193-212. [PMID: 32935346 DOI: 10.1111/nyas.14473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Huerta-Iga FM, Tamayo-de la Cuesta JL, Noble-Lugo A, Remes-Troche JM, Valdovinos-Díaz MA, Carmona-Sánchez RI; el Grupo Mexicano para el Estudio de la Enfermedad por Reflujo Gastroesofágico 2011. [The Mexican consensus on gastroesophageal reflux disease. Part I]. Rev Gastroenterol Mex 2012;77:193-213. [PMID: 23153413 DOI: 10.1016/j.rgmx.2012.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Savarino E, Zentilin P, Marabotto E, Bodini G, Della Coletta M, Frazzoni M, de Bortoli N, Martinucci I, Tolone S, Pellegatta G, Savarino V. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opin Pharmacother. 2017;18:1333-1343. [PMID: 28754071 DOI: 10.1080/14656566.2017.1361407] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
8 Dutta U, Moayyedi P. Management of reflux-related symptoms. Best Pract Res Clin Gastroenterol 2013;27:387-400. [PMID: 23998977 DOI: 10.1016/j.bpg.2013.06.004] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: A meta-analysis. World J Gastroenterol 2014; 20(9): 2412-2419 [PMID: 24605040 DOI: 10.3748/wjg.v20.i9.2412] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
10 Rada RE. Dental erosion due to GERD in patients with developmental disabilities: case theory: DENTAL EROSION DUE TO GERD. Special Care in Dentistry 2014;34:7-11. [DOI: 10.1111/scd.12055] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
11 Yu YY, Fang DC, Fan LL, Chang H, Wu ZL, Cao Y, Lan CH. Efficacy and safety of esomeprazole with flupentixol/melitracen in treating gastroesophageal reflux disease patients with emotional disorders. J Gastroenterol Hepatol 2014;29:1200-6. [PMID: 24955450 DOI: 10.1111/jgh.12552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
12 Silva RO, Bingana RD, Sales TMAL, Moreira RLR, Costa DVS, Sales KMO, Brito GAC, Santos AA, Souza MÂN, Soares PMG, Sifrim D, Souza MHLP. Role of TRPV1 receptor in inflammation and impairment of esophageal mucosal integrity in a murine model of nonerosive reflux disease. Neurogastroenterol Motil 2018;30:e13340. [DOI: 10.1111/nmo.13340] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
13 Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Current Opinion in Gastroenterology 2019;35:344-55. [DOI: 10.1097/mog.0000000000000543] [Cited by in Crossref: 12] [Article Influence: 4.0] [Reference Citation Analysis]
14 Scarpignato C, Gatta L. Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. In: Morice AH, Dettmar PW, editors. Reflux Aspiration and Lung Disease. Cham: Springer International Publishing; 2018. pp. 269-91. [DOI: 10.1007/978-3-319-90525-9_23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Manabe N, Haruma K, Ito M, Takahashi N, Takasugi H, Wada Y, Nakata H, Katoh T, Miyamoto M, Tanaka S. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus. 2012;25:373-380. [PMID: 22050449 DOI: 10.1111/j.1442-2050.2011.01276.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
16 Stull DE, van Hanswijck de Jonge P, Houghton K, Kocun C, Sandor DW. Development of a Frequent Heartburn Index. Qual Life Res 2011;20:1023-34. [DOI: 10.1007/s11136-010-9840-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20:2412-2419. [PMID: 24605040 DOI: org/10.3748/wjg.v20.i9.2412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Ceriotti L, Buratti P, Corazziari ES, Meloni M. Protective Mechanisms of Liquid Formulations for Gastro-Oesophageal Reflux Disease in a Human Reconstructed Oesophageal Epithelium Model. MDER 2022;Volume 15:143-52. [DOI: 10.2147/mder.s363616] [Reference Citation Analysis]